Travatan(travoprost)
DuoTrav, Izba, Travatan (travoprost) is a small molecule pharmaceutical. Travoprost was first approved as Travatan on 2001-03-16. It is used to treat open-angle glaucoma in the USA. It has been approved in Europe to treat ocular hypertension and open-angle glaucoma.
Download report
Favorite
Novartis Pharmaceuticals
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| eye diseases | D005128 |
Trade Name
FDA
EMA
Travatan (generic drugs available since 2013-03-01, discontinued: Izba)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Travoprost
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TRAVATAN Z | Novartis | N-021994 RX | 2006-09-21 | 1 products, RLD, RS |
Show 2 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| travatan z | New Drug Application | 2020-05-15 |
| travoprost | ANDA | 2022-12-15 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| open-angle glaucoma | EFO_0004190 | D005902 | H40.1 |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
130 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ocular hypertension | D009798 | EFO_1001069 | H40.0 | 1 | 13 | 30 | 32 | 9 | 85 |
| Open-angle glaucoma | D005902 | EFO_0004190 | H40.1 | — | 10 | 26 | 25 | 10 | 71 |
| Glaucoma | D005901 | EFO_0000516 | H40 | 2 | 4 | 6 | 29 | 5 | 46 |
| Intraocular pressure | D007429 | — | — | — | 3 | 1 | 4 | ||
| Angle-closure glaucoma | D015812 | — | — | 1 | 1 | — | 2 | ||
| Vitiligo | D014820 | EFO_0004208 | L80 | — | — | — | 1 | — | 1 |
| Excimer lasers | D054018 | — | — | — | 1 | — | 1 | ||
| Hyperemia | D006940 | EFO_0003822 | H34.82 | — | — | — | 1 | — | 1 |
| Low tension glaucoma | D057066 | EFO_1001022 | H40.12 | — | — | — | 1 | — | 1 |
| Macular edema | D008269 | — | — | — | 1 | — | 1 |
Show 2 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Exfoliation syndrome | D017889 | EFO_0004235 | — | — | 1 | — | 1 | 2 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neovascular glaucoma | D015355 | EFO_1001060 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TRAVOPROST |
| INN | travoprost |
| Description | Travoprost is the isopropyl ester of prostaglandin F2alpha in which the pentyl group is replaced by a 3-(trifluoromethyl)phenoxymethyl group. A synthetic analogue of prostaglandin F2alpha, ophthalmic solutions of travoprost are used as a topical medication for controlling the progression of open-angle glaucoma and ocular hypertension, by reducing intraocular pressure. It is a pro-drug; the isopropyl ester group is hydrolysed by esterases in the cornea to the biologically active free acid, fluprostenol. It has a role as an antiglaucoma drug, an antihypertensive agent, a prodrug, an ophthalmology drug and a prostaglandin receptor agonist. It is a prostaglandins Falpha, a member of (trifluoromethyl)benzenes and an isopropyl ester. It is functionally related to a fluprostenol. |
| Classification | Small molecule |
| Drug class | prostaglandins |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COc1cccc(C(F)(F)F)c1 |
Identifiers
| PDB | — |
| CAS-ID | 157283-68-6 |
| RxCUI | 283809 |
| ChEMBL ID | CHEMBL1200799 |
| ChEBI ID | 746859 |
| PubChem CID | 5282226 |
| DrugBank | DB00287 |
| UNII ID | WJ68R08KX9 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Travoprost - Novartis
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,654 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5,418 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more